COMPOSITIONS AND METHODS FOR MODULATING CELL DIFFERENTIATION

• US 20090221072A1
• Filed: 05/13/2009
• Published: 09/03/2009
• Est. Priority Date: 02/15/2006
• Status: Abandoned Application

• Current Assignee: EP Therapeutics, Inc.
• Original Assignee: EP Therapeutics, Inc.
• Inventors: Chen, Thomas T., Chen, Maria J.M.
• Application Number:
  US12/465,053
• Publication Number:
  US 20090221072A1
• Time in Patent Office: Days
• US Class Current: 435/377
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754

Abstract

Compositions and methods are described for using the Ea4-peptide of pro-IGF-I or human Eb-peptide of pro-IGF-I to inhibit hematopoiesis and to induce differentiation of neuroblastoma cells and neuronal stem cells.

Claims

1. A method for inhibiting the differentiation of a progenitor cell, comprising treating the progenitor cell with a composition comprising an effective amount of an insulin-like growth factor (IGF-1) E-domain peptide together with at least one of a pharmaceutically acceptable carrier, excipient or adjuvant, wherein the composition inhibits cell differentiation.

2. The method of claim 1, wherein the progenitor cell is a stem cell.

3. The method of claim 1, wherein the progenitor cell is a hematopoietic stem cell.

4. The method of claim 3, wherein the neuronal stem cell is a pituitary stem cell.

5. The method of claim 1, wherein the composition comprises at least one E-domain peptide having the amino acid sequence as set forth in SEQ ID NO:

2, having the amino acid sequence as set forth in SEQ ID NO;

1, or a combination of both.

6. The method of claim 5, wherein the composition comprises a fusion protein having an E-domain peptide joined in a contiguous polypeptide chain with a non-E-domain peptide.

7. A cell generated according to the method of claim 1.

8. A method for promoting the differentiation of a neuronal progenitor cell, comprising treating a neuronal progenitor cell with a composition comprising an effective amount of an E-domain peptide together with at least one of a pharmaceutically acceptable carrier, excipient or adjuvant, wherein the composition promotes differentiation of the neuronal progenitor cell.

9. The method of claim 8, wherein the neuronal progenitor cell is at least one of a primary neuronal stem cell or a neuronal tumor progenitor cell.

10. The method of claim 9, wherein the primary neuronal stem cell is a pituitary stem cell.

11. The method of claim 9, wherein the neuronal tumor progenitor cell is a neuroblastoma cell.

12. The method of claim 8, wherein the composition comprises at least one of an E-domain peptide having the amino acid sequence as set forth in SEQ ID NO:

2, having the amino acid sequence as set forth in SEQ ID NO;

1, or a combination or both.

13. The method of claim 12, wherein the composition comprises a fusion protein having an E-domain peptide joined in a contiguous polypeptide chain with a non-E-domain peptide.

14. A method for the suppression of the malignant growth of a neuroblastoma cell comprising, treating a neuroblastoma cell with an effective amount of an E-domain peptide together with at least one of a pharmaceutically acceptable carrier, excipient or adjuvant, wherein the composition promotes neuroblastoma cell differentiation.

15. The method of claim 14, wherein the composition comprises at least one of an E-peptide having the amino acid sequence as set forth in SEQ ID NO:

2, having the amino acid sequence as set forth in SEQ ID NO;

1, or a combination of both.

16. The method of claim 15, wherein the composition comprises a fusion protein having an E-domain peptide joined in a contiguous polypeptide chain with a non-E-domain peptide.